ArticleTherapeutic advances in medical oncology2024

Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study.

Qingyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.